Ana is a molecular biologist with a passion for discovery and communication. As a science writer she is passionate about connecting the public, in particular patient and healthcare communities, to clear and quality information about the latest medical advances. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in genetics, molecular biology, and infectious diseases. She is also a nature and music lover!
Treatments conventionally used for myasthenia gravis (MG) can produce side effects that negatively impact the daily lives of patients and may deter them from taking their medications properly, according ... Read more
Amneal has signed a licensing agreement with Kashiv BioSciences to develop and potentially commercialize K127, an extended-release tablet of pyridostigmine, for the treatment of myasthenia gravis (MG) in the United ... Read more
Treatment with Soliris (eculizumab) provides comparable and sustained improvements in daily living and muscle strength in Japanese and Caucasian patients with treatment-resistant generalized myasthenia gravis (gMG), according to one-year data of ... Read more
People with myastenia gravis (MG) whose disease is refractory, or resistant, to conventional therapies, are more likely to have disease flare-ups, visit an emergency room, be hospitalized, or be ... Read more
Examining differences in the activity of certain genes may help explain why some patients with myasthenia gravis (MG) develop a difficult-to-treat form of the disease in the eyes. Researchers ... Read more
Placebo-treated myasthenia gravis (MG) patients experience as many adverse events as those receiving an active treatment during clinical trials, but this leads to few participant dropouts — and should ... Read more
Pin It on Pinterest